Assignee
INNATE PHARMA
FR·57 granted patents·56 pending applications·311 citations·filing 2006–2025
Top patents by PatentIndex Score
113 records- 0197US9717803B2Enzymatic conjugation of polypeptidesINNATE PHARMA·Filed 2012·Granted Aug 1, 2017·29 cites·40 claims
- 0296US11958907B2CD73 blockadeINNATE PHARMA·Filed 2020·Granted Apr 16, 2024·4 cites·21 claims
- 0396US10675359B2Enzymatic conjugation of antibodiesINNATE PHARMA·Filed 2017·Granted Jun 9, 2020·11 cites·24 claims
- 0496US9764038B2Enzymatic conjugation of antibodiesINNATE PHARMA·Filed 2012·Granted Sep 19, 2017·38 cites·13 claims
- 0595US11891444B2Variable regions for NKp46 binding proteinsINNATE PHARMA·Filed 2021·Granted Feb 6, 2024·3 cites·15 claims
- 0695US11572410B2Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2020·Granted Feb 7, 2023·3 cites·5 claims
- 0795US10329348B2Treatment of cancers using anti-NKG2A agentsINNATE PHARMA·Filed 2015·Granted Jun 25, 2019·16 cites·15 claims
- 0894US11267897B2Multispecific NK engager proteinINNATE PHARMA·Filed 2018·Granted Mar 8, 2022·8 cites·19 claims
- 0994US10577419B2KIR3DL2 binding agentsINNATE PHARMA·Filed 2015·Granted Mar 3, 2020·15 cites·10 claims
- 1094US10434180B2Enzymatic conjugation of polypeptidesINNATE PHARMA·Filed 2016·Granted Oct 8, 2019·20 cites·13 claims
- 1194US9427478B2Enzymatic conjugation of polypeptidesINNATE PHARMA·Filed 2014·Granted Aug 30, 2016·30 cites·21 claims
- 1293US10711063B2Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2015·Granted Jul 14, 2020·8 cites·13 claims
- 1393US10113003B2Multispecific NK engager proteinsINNATE PHARMA·Filed 2016·Granted Oct 30, 2018·15 cites·28 claims
- 1492US10676523B2Treatment regimens using anti-NKG2A antibodiesINNATE PHARMA·Filed 2015·Granted Jun 9, 2020·7 cites·10 claims
- 1591US11066470B2Humanized antibodies with increased stabilityINNATE PHARMA·Filed 2019·Granted Jul 20, 2021·3 cites·13 claims
- 1690US11078275B2Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphomaINNATE PHARMA·Filed 2019·Granted Aug 3, 2021·3 cites·12 claims
- 1790US10280222B2Humanized antibodies with increased stabilityINNATE PHARMA·Filed 2015·Granted May 7, 2019·8 cites·7 claims
- 1890US10174112B2Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphomaINNATE PHARMA·Filed 2017·Granted Jan 8, 2019·9 cites·12 claims
- 1989US11692039B2Multifunctional natural killer (NK) cell engagers binding to NKp46 and CD123INNATE PHARMA·Filed 2021·Granted Jul 4, 2023·2 cites·22 claims
- 2089US11377503B2Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptideINNATE PHARMA·Filed 2019·Granted Jul 5, 2022·3 cites·13 claims
- 2189US10870700B2Neutralization of inhibitory pathways in lymphocytesINNATE PHARMA·Filed 2017·Granted Dec 22, 2020·6 cites·16 claims
- 2289US10766966B2CD73 blockadeINNATE PHARMA·Filed 2015·Granted Sep 8, 2020·5 cites·12 claims
- 2389US10246510B2KIR3DL2 binding agentsINNATE PHARMA·Filed 2013·Granted Apr 2, 2019·9 cites·20 claims
- 2488US11858990B2KIR3DL2 binding agentsINNATE PHARMA·Filed 2020·Granted Jan 2, 2024·2 cites·7 claims
- 2588US11001629B2Variable regions for NKp46 binding proteinsINNATE PHARMA·Filed 2016·Granted May 11, 2021·7 cites·6 claims
- 2688US9828427B2Anti-KIR3D antibodiesINNATE PHARMA·Filed 2015·Granted Nov 28, 2017·9 cites·7 claims
- 2787US11225519B2Treatment of cancers using anti-NKG2A agentsINNATE PHARMA·Filed 2019·Granted Jan 18, 2022·3 cites·18 claims
- 2887US11078274B2Siglec neutralizing antibodiesINNATE PHARMA·Filed 2017·Granted Aug 3, 2021·3 cites·23 claims
- 2987US2025092130A1Compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphomaINNATE PHARMA·Filed 2024·Application pending·0 cites
- 3086US10519234B2NKp46 binding proteinsINNATE PHARMA·Filed 2015·Granted Dec 31, 2019·6 cites·12 claims
- 3185US11208480B2Multispecific antigen binding proteinsINNATE PHARMA·Filed 2015·Granted Dec 28, 2021·3 cites·8 claims
- 3284US2024368281A1Treatment regimens using anti-nkg2a antibodiesINNATE PHARMA·Filed 2024·Application pending·0 cites
- 3383US11130817B2CD73 blocking agentsINNATE PHARMA·Filed 2016·Granted Sep 28, 2021·3 cites·5 claims
- 3483US10071169B2Enzymatic conjugation of polypeptidesINNATE PHARMA·Filed 2014·Granted Sep 11, 2018·3 cites·27 claims
- 3583US10036010B2Recognition tags for TGase-mediated conjugationINNATE PHARMA·Filed 2013·Granted Jul 31, 2018·4 cites·8 claims
- 3682US10344087B2Treatment of peripheral T cell lymphomaINNATE PHARMA·Filed 2014·Granted Jul 9, 2019·3 cites·7 claims
- 3782US2024425586A1Treatment of peripheral t cell lymphomaINNATE PHARMA·Filed 2024·Application pending·0 cites
- 3880US11845795B2NKp46 binding proteinsINNATE PHARMA·Filed 2019·Granted Dec 19, 2023·1 cites·12 claims
- 3980US2024124579A1Kir3dl2 binding agentsINNATE PHARMA·Filed 2023·Application pending·0 cites
- 4079US12202907B2Nucleic acids encoding and methods of producing proteins comprising antibody chainsINNATE PHARMA·Filed 2022·Granted Jan 21, 2025·0 cites·36 claims
- 4179US10736963B2Methods for detecting tissue infiltrating NK cellsINNATE PHARMA·Filed 2016·Granted Aug 11, 2020·2 cites·5 claims
- 4279US2024174748A1Variable regions for nkp46 binding proteinsINNATE PHARMA·Filed 2024·Application pending·0 cites
- 4379US2024391999A1Treatment with anti-kir3dl2 agentsINNATE PHARMA·Filed 2024·Application pending·0 cites
- 4478US11623954B2Siglec-9-neutralizing antibodiesINNATE PHARMA·Filed 2018·Granted Apr 11, 2023·1 cites·12 claims
- 4578US11377492B2NKp46 binding agentsINNATE PHARMA·Filed 2018·Granted Jul 5, 2022·1 cites·16 claims
- 4678US10132799B2Screening of conjugated antibodiesINNATE PHARMA·Filed 2013·Granted Nov 20, 2018·3 cites·22 claims
- 4778US2024141042A1MULTISPECIFIC NKp46 BINDING PROTEINSINNATE PHARMA·Filed 2023·Application pending·0 cites
- 4877US12227569B2Humanized antibodies with increased stabilityINNATE PHARMA·Filed 2021·Granted Feb 18, 2025·0 cites·14 claims
- 4977US11578136B2Compositions and methods for treating cancerINNATE PHARMA·Filed 2018·Granted Feb 14, 2023·1 cites·12 claims
- 5076US12084498B2Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphomaINNATE PHARMA·Filed 2021·Granted Sep 10, 2024·0 cites·13 claims
Showing the top 50 of 113 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when INNATE PHARMA files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →